Biotech billionaire faces accusations of fraud for $1.3B 'catch-and-kill' cancer drug deal
When biotech billionaire Patrick Soon-Shiong arranged a $90 million upfront payment to Sorrento from NantPharma 4 years ago to acquire Cynviloq — promising $1.2 billion more in milestones — he heralded the deal, saying an “opportunity to develop combination regimens of low-dose metronomic use of this active drug is an important step in transforming cancer care as we know it today.”
For his part, Sorrento CEO Henry Ji said he was “excited” that Soon-Shiong had stepped in to speed these new combos along.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.